amit@unlistedkraft.in
+91-9599071664
+91-9599071664
PharmEasy Unlisted Shares
DRHP Status : Not Filed
6.4
Fundamentals About PharmEasy
Downloads & Investor Documents
All documents are provided for informational purposes and are subject to regulatory disclosures.
Key Financials of PharmEasy
| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 5729 | 6644 | 5664 | 5872 |
| Cost of Material Consumed | 5342 | 5669 | 4737 | 4918 |
| Change in Inventory | -229 | 62 | 143 | -4 |
| Gross Margins | 10.75 | 13.74 | 13.84 | 16.31 |
| Employee Benefit Expenses | 1459 | 1283 | 699 | 908 |
| Other Expenses | 1502 | 1051 | 731 | 711 |
| EBITDA | -2345 | -1421 | -646 | -661 |
| OPM | -40.93 | -21.39 | -11.41 | -11.26 |
| Other Income | -1185 | -2866 | 931 | -181 |
| Finance Cost | 258 | 666 | 728 | 506 |
| D&A | 159 | 243 | 216 | 169 |
| EBIT | -2504 | -1664 | -862 | -830 |
| EBIT Margins | -43.71 | -25.05 | -15.22 | -14.13 |
| PBT | -3977 | -5196 | -2522 | -1517 |
| PBT Margins | -69.42 | -78.21 | -44.53 | -25.83 |
| Tax | 22 | 15 | 11 | 55 |
| PAT | -3999 | -5211 | -2533 | -1572 |
| NPM | -69.8 | -78.43 | -44.72 | -26.77 |
| EPS | -6.51 | -8.48 | -3.9 | -2.26 |
| Financial Ratios | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | -40.93 | -21.39 | -11.41 | -11.26 |
| Net Profit Margin | -69.8 | -78.43 | -44.72 | -26.77 |
| Earning Per Share (Diluted) | -6.51 | -8.48 | -3.9 | -2.26 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 1025 | 912 | 734 | 662 |
| CWIP | 7.8 | 4 | 3.6 | 14 |
| Investments | 438 | 342 | 329 | 179 |
| Trade Receivables | 861 | 905 | 706 | 670 |
| Inventory | 761 | 688 | 556 | 554 |
| Other Assets | 8305.2 | 5405 | 6061.4 | 4898 |
| Total Assets | 11398 | 8256 | 8390 | 6977 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 614.2 | 614.2 | 649.6 | 694.9 |
| FV | 1 | 1 | 1 | 1 |
| Reserves | 6408.3 | 1823 | 1938 | 2577 |
| Borrowings | 2585 | 4120 | 4098 | 2034 |
| Trade Payables | 459 | 413 | 413 | 426.6 |
| Other Liabilities | 1331.5 | 1285.8 | 1291.4 | 1244.5 |
| Total Liabilities | 11398 | 8256 | 8390 | 6977 |
About Company
The following table shows a 10-point analysis of PharmEasy (API Holdings Limited). We will discuss each point in detail after this table.
| Parameter | Key Numbers | Insights |
|---|---|---|
| Business Overview | FY25 Revenue ₹5,872 cr · PAT loss ₹1,572 cr · PAT margin ~-27% | Leading e-pharmacy & diagnostics platform; offers medicines, lab tests, teleconsultations & B2B services; major revenue from pharma sales (~87%); undergoing heavy cost optimisation with reduced exceptional losses but remains loss-making due to depreciation, finance costs & prior impairments. |
| Industry & Market Position | Largest e-pharmacy player by revenue · Strong diagnostics presence (Thyrocare) · Benefits from digital healthcare adoption | Dominant in organised online pharma but faces intense competition (1mg, Netmeds, Amazon Pharmacy); edge from scale, brand recognition & integrated model; resilient via B2B & diagnostics vertical; exposed to regulatory risks (drug pricing, e-pharmacy norms) & industry policy changes. |
| Revenue Growth Trend | FY24 ₹5,664 cr → FY25 ₹5,872 cr · ~3.7% YoY growth | Revenue stabilised after prior volatility; growth muted due to strategic shift toward profitability over expansion; long-term tailwinds from digital health adoption, though recent performance reflects consolidation phase. |
| Profitability & Margins | EBITDA loss ₹553 cr (~-9.4%) · ROE negative · PAT margin negative | Losses narrowed ~38–40% YoY due to lower exceptional items & cost rationalisation (employee & other expenses optimised); still negative owing to high depreciation & finance costs; operational improvements visible but sustainable profitability pending. |
| Cash Flow Quality | OCF negative (~₹115 cr outflow) · No dividends (loss phase) | Continued cash burn from operations & capex; supported by debt raises & historical funding; working capital & interest obligations pressure liquidity timing; quality moderate during transition. |
| Balance Sheet Strength | Net worth pressured (reserves erosion) · Debt moderate/high (elevated gearing) | Increased leverage post-funding; liquidity managed via debt & selective asset monetisation; downside partly protected by diagnostics stake & brand value, though elevated debt & ongoing losses raise financial risk. |
| Valuation Comfort | Unlisted price ~₹5.5–6.5 (Feb 2026 range) · Market cap ~₹3,900–4,500 cr | Deeply discounted valuation reflecting sustained losses & reset expectations; highly speculative; limited premium despite scale; suitable mainly as turnaround or IPO-revival bet. |
| Management & Governance | Professional management with investor backing · Transparent disclosures | Demonstrated execution in cost control & diagnostics integration; clean regulatory filings & annual reports; governance standards appear stable despite financial stress. |
| Growth Triggers & Catalysts | Cost optimisation · Diagnostics recovery · Potential IPO relaunch | Upside dependent on operational efficiency, B2B expansion & broader digital healthcare adoption; further loss reduction critical; IPO revival would serve as major valuation catalyst. |
| Liquidity & Exit Visibility | OTC liquidity only · IPO plans pending (previous DRHP withdrawn) | Limited unlisted trading liquidity; capital largely locked; exit risk elevated until profitability improves or IPO materialises; speculative profile. |
PharmEasy, founded in 2015, is an Indian healthcare-tech company operating primarily as an online pharmacy, diagnostics platform and telehealth service. The following are the key points about PharmEasy
- It provides medicines (prescription and OTC), healthcare products, diagnostic tests (home-sample collection) and teleconsultation services.
- It claims broad geographic reach, covering thousands of pin-codes across India, and integrates a network of pharmacies, labs and logistics.
- The parent company, API Holdings Ltd, holds PharmEasy and diagnostics entity Thyrocare, among others.
History & Key Milestones
- Founded by Dharmil Sheth, Dhaval Shah, Siddharth Shah and others in Mumbai in 2015.
- In 2021, PharmEasy (via API Holdings) acquired a controlling stake (66%) in diagnostics chain Thyrocare Technologies Ltd, expanding its diagnostics footprint.
- The company has raised large amounts of funding ($1 billion+ to date) from investors such as Temasek, Prosus, TPG, MEMG.
- In recent years it has undergone a leadership change (co-founders stepping back) and financial restructuring.
Business Model & Revenue Streams
- Medicine & healthcare product sales: The largest chunk of revenue comes from selling medicines/healthcare products online and through partner pharmacies.
- Diagnostics & telehealth services: Fees from diagnostic tests (sample collection + lab partner), teleconsultations, health-check packages.
- Memberships & value-added services: Subscriptions or premium programmes for frequent users (e.g., faster delivery, discounts).
- Platform & logistics integration: The company invests in its own logistics, warehousing and fulfilment, to support its pharmacy/diagnostic operations.
- Cross-sell & network effect: By integrating pharmacies, diagnostics, and telehealth, the company aims for a holistic “super-app” in healthcare.
Financial Performance & Key Metrics
- For FY25, API Holdings (PharmEasy’s parent) reported revenue of ₹ 5,872 crore, up 3.7% from FY24.
- Net loss for FY25 stood at ₹ 1,572.3 crore, compared with ₹ 2,533.5 crore in FY24 — a narrowing of the loss by 38%.
- EBITDA loss for FY25 was ₹ 553.5 crore; margin remained negative (-15.7%).
- The company has a significant debt and financing cost burden; in Sept 2025 it raised ₹ 1,700 crore via NCDs by pledging 61% of Thyrocare stake.
- FY24 saw revenue decline of 14.7% to ₹ 5,664 crore from FY23 (₹ 6,643 crore), as the company focused on higher-margin customers.
Strengths & Growth Drivers
- Large addressable market: The Indian online pharmacy + diagnostics market is large and under-penetrated, offering long-term growth.
- Integrated healthcare platform: With operations across pharmacy, diagnostics and telehealth, PharmEasy has multiple levers.
- Strong brand and reach: Among the early movers in e-pharmacy, with wide geographic coverage.
- Backed by major investors: That gives credibility and capital for scaling.
- Cost rationalisation underway: Recent focus on improving unit economics and reducing losses indicates improved discipline.
Risks & Challenges
- Negative profitability: The Company remains unprofitable with high losses and negative margins.
- High cost structure: Logistics, warehousing, regulatory compliance and marketing are capital-intensive.
- Debt and financing risk: Heavy debt, pledge of Thyrocare shares, and refinancing risk present concerns.
- Regulatory risk: E-pharmacy and diagnostics operate in regulated industries; policy changes can impact business.
- Competition: Intense competition from other platforms (Tata 1mg, Netmeds, etc) and offline players.
- Customer behaviour & margins: Online pharmacy margins are thin; price competition and low switching costs are challenges.
Quick Summary
PharmEasy (API Holdings) is a leading Indian digital healthcare company with a wide business model spanning online pharmacy, diagnostics and telemedicine. It has scale, brand strength and a large addressable market. However, it is still in the red, facing profitability and debt challenges. The upcoming years will be critical as it works to turn around finances, improve unit economics and scale profitably. For unlisted-share investors, it’s a high potential but high risk healthcare investment — the market opportunity is huge, but execution and regulatory risks are real.
Shareholding Pattern of PharmEasy
| Name | Holding |
|---|---|
| Naspers Ventures B. V | 12.48% |
| MacRitchie Investments Pte. Ltd. | 11.24% |
| TPG Growth V SF Markets Pte. Ltd. | 6.09% |
| Evermed Holding Pte. Ltd | 6.08% |
| Others | 63.3% |
Promoters of PharmEasy
| Name | Designation | Linkedin Profile |
|---|---|---|
| Dharmil Sheth | Co-Founder |  |
| Dhaval Shah | Co-Founder | |
| Siddharth Shah | Former CEO & Co-Founder | |
| Rahul Guha | MD & CEO (API Holdings) | |
Latest News
Latest Post
.webp)
Coming soon...
Coming soon...
Frequently Asked Questions
These are equity shares of API Holdings (the parent company of PharmEasy), one of India’s largest digital healthcare and online pharmacy companies. Since the company is not yet listed on NSE/BSE, the shares are traded privately through platforms like UnlistedKraft.
Yes. You can place an order through UnlistedKraft after completing a simple KYC. Shares are typically credited to your demat account within 24 hours.
All unlisted investments involve risk. However, PharmEasy is a major healthcare startup backed by global investors. Buying through UnlistedKraft ensures secure, verified transactions and transparent pricing.
Prices depend on recent grey-market trades, demand from investors, company valuation movements, and industry trends. UnlistedKraft updates prices regularly for fair value.
Yes, a demat account is compulsory to receive and hold unlisted shares of PharmEasy.
Yes. SEBI mandates a six-month lock-in after listing for pre-IPO shares bought in the unlisted market.
Yes. UnlistedKraft allows resale of unlisted shares subject to market demand and availability of buyers.
As the company is loss-making and has recently restructured debt and operations, the investment carries high risk and long-term holding expectation.
Holding for over two years qualifies for long-term capital gains tax at 20% with indexation. Selling within two years attracts short-term capital gains as per your income tax slab.
UnlistedKraft provides verified access to PharmEasy shares with transparent pricing, fast settlements, secure transfer, and expert guidance throughout the buying and selling process.
+91-9599071664
amit@unlistedkraft.in